TIGIT对血液淋巴系统恶性肿瘤的免疫调节作用  

Immunomodulatory effects of TIGIT on hematological malignancies

作　　者：王约拿 刘佳[1] 李莉娟[1] 张连生[1] WANG Yue-na;LIU Jia;LI Li-juan;ZHANG Lian-sheng(Department of Hematology,Lanzhou University Second Hospital,Lanzhou,Gansu 730000,China)

机构地区：[1]兰州大学第二医院血液科,甘肃兰州730030

出　　处：《中国临床研究》2022年第6期854-857,共4页Chinese Journal of Clinical Research

摘　　要：T细胞免疫球蛋白和免疫受体酪氨酸抑制性基序结构域(TIGIT)是一种新的免疫检查点受体,是主要表达于T细胞和自然杀伤细胞(NK细胞)表面的一种免疫抑制性受体,通过抑制T细胞和NK细胞介导的免疫反应影响肿瘤微环境,促进肿瘤的发生发展。本文介绍TIGIT分子的结构与功能,并对TIGIT分子在血液淋巴系统恶性肿瘤的免疫调控、应用和前景作一综述。T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain(TIGIT) is a novel type of immune checkpoint receptor and an immunosuppressive receptor mainly expressed on the cell surface of T cells and NK cells. TIGIT affects the tumor microenvironment and promotes the occurrence and development of tumor by inhibiting the immune response mediated by T cells and NK cells. This paper introduces the structure and function of TIGIT molecule and reviews its immune regulation, application and prospect in hematological malignancies.

关 键 词：T细胞免疫球蛋白和免疫受体酪氨酸抑制性基序结构域 免疫调节 血液淋巴系统恶性肿瘤 免疫检查点阻断剂 

分 类 号：R733[医药卫生—肿瘤]